Production using the new expanded capacity at its multi-product cGMP active pharmaceutical ingredient (API) manufacturing facility commenced on 1 June 2012.
The investment matches the solids handling equipment with the reactor capacity and is expected to allow the company to advance its portfolio of custom API products, several of which have progressed to late stage clinical development and pre-registration status.
Albemarle uses the Quality by Design approach to establish manufacturing processes and then speed validated commercial products to market, according to the company.